112 related articles for article (PubMed ID: 4836072)
1. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
Ludwig E; Lechner K
Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
[No Abstract] [Full Text] [Related]
2. [Hemophilia BM (abnormal factor IX in coagulation disorder) (author's transl)].
Girolami A; Cella G; Patrassi G
Haematologica; 1974 Mar; 59(1):91-108. PubMed ID: 4212668
[No Abstract] [Full Text] [Related]
3. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
Siegmund B; Richter H; Pollmann H
Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
[TBL] [Abstract][Full Text] [Related]
5. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
6. [Results of a cooperative programme of profilactic treatment for haemophilia A and B (author's transl)].
Sangre (Barc); 1978; 23(5B):780-92. PubMed ID: 725718
[No Abstract] [Full Text] [Related]
7. Evaluation of a new concentrate for the treatment of factor IX deficiency.
Gilchrist GS; Ekert H; Shanbrom E; Hammond D
N Engl J Med; 1969 Feb; 280(6):291-5. PubMed ID: 5762370
[No Abstract] [Full Text] [Related]
8. Prophylaxis in haemophilia B patients: unresolved issues and pharmacoeconomic implications.
Santagostino E
Haemophilia; 2010 Jul; 16 Suppl 6():13-7. PubMed ID: 20561353
[No Abstract] [Full Text] [Related]
9. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
Haanen C; McShine RL; Kunst A
Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
[No Abstract] [Full Text] [Related]
10. [A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl)].
Schimpf K; Baumann P
Dtsch Med Wochenschr; 1976 Feb; 101(7):233-8. PubMed ID: 1248406
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Aledort LM
Haemophilia; 2010 Jul; 16 Suppl 6():1-2. PubMed ID: 20561350
[TBL] [Abstract][Full Text] [Related]
12. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
13. Substitution treatment of hemophilia a and b.
Duckert F
Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
[TBL] [Abstract][Full Text] [Related]
14. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
[TBL] [Abstract][Full Text] [Related]
15. [A factor IX-concentrate for the treatment of haemophilia B].
Suomela H; Myllylä G
Duodecim; 1971; 87(1):31-8. PubMed ID: 5539580
[No Abstract] [Full Text] [Related]
16. The management of deep soft tissue bleeding and hemarthrosis in hemophilia.
Miller EH; Flessa HC; Glueck HI
Clin Orthop Relat Res; 1972; 82():92-107. PubMed ID: 5011042
[No Abstract] [Full Text] [Related]
17. [New viewpoints in the treatment of hemophilia].
Göbel U
Dtsch Med Wochenschr; 1973 Sep; 98(39):1814-6. PubMed ID: 4583442
[No Abstract] [Full Text] [Related]
18. [Preparation of factor IX concentrate with the use of DEAE-cellulose and its therapeutic results].
Uszyński L; Poszwiński P
Acta Haematol Pol; 1971; 2(2):109-14. PubMed ID: 5170671
[No Abstract] [Full Text] [Related]
19. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
20. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
